I-01 Annika Schneider Physiologically based pharmacokinetic modeling – application for renal and hepatic impairment Wednesday 10:10-11:40 |
I-18 Konstantinos Stamatopoulos A Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts Model Wednesday 10:10-11:40 |
I-36 Kota Toshimoto Application of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effect Wednesday 10:10-11:40 |
I-39 Denise Feick Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone Wednesday 10:10-11:40 |
I-45 Erno van Schaick Simulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic model Wednesday 10:10-11:40 |
II-07 Kevin Feng Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies Wednesday 15:50-17:20 |
II-35 Silvia Grandoni Evaluating the inclusion of the particle size distribution in the lung dissolution model of a WB-PBPK model to describe the pharmacokinetics of inhaled polydisperse drugs. Wednesday 15:50-17:20 |
II-38 Felix Hammann Whole-body physiology pharmacokinetic modeling of flip-flop behavior of oral oxycodone solution in pediatric patients 5-16 years old Wednesday 15:50-17:20 |
II-39 Niklas Hartung A size- and location-structured model for pulmonary absorption, elimination and dissolution of an orally inhaled drug Wednesday 15:50-17:20 |
II-47 Wilhelm Huisinga Cell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment Wednesday 15:50-17:20 |
II-50 Ibrahim Ince A Population Physiologically-Based Pharmacokinetic Model for prediction of pharmacokinetics of small molecule drugs in healthy Japanese adults: Bridging PBPK from Caucasian to Japanese ethnicity Wednesday 15:50-17:20 |
II-66 Tobias Kanacher Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors Wednesday 15:50-17:20 |
II-68 Eleni Karatza Mathematical modeling of gastric emptying: a joint model for losartan and its active metabolite EXP-3174 Wednesday 15:50-17:20 |
III-03 Amais Ahmad Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption Thursday 09:55-11:30 |
III-07 Muhammad Waqar Ashraf A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers. Thursday 09:55-11:30 |
III-11 Vanessa Baier Developing a physiology-based model of bile acid metabolism in men Thursday 09:55-11:30 |
III-12 Pavel Balazki A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP Thursday 09:55-11:30 |
III-18 Roberta Bartolucci A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans Thursday 09:55-11:30 |
III-31 Hannah Britz Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine Thursday 09:55-11:30 |
III-48 Manoranjenni Chetty Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging Thursday 09:55-11:30 |
III-59 André Dallmann Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling Thursday 09:55-11:30 |
III-65 Mailys De Sousa Mendes Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol Thursday 09:55-11:30 |
III-68 Neel Deferm A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes Thursday 09:55-11:30 |
IV-23 Jialin Mao PBPK modelling of drug-drug interactions driven by moderate CYP3A inducers Thursday 15:10-16:40 |
IV-30 Matilde Merino-Sanjuán Evaluation of the impact of undernourishment on the intestinal absorption of gefitinib in rats. Thursday 15:10-16:40 |
IV-44 Andrés Olivares-Morales Switching from immediate release to modified release can have an impact on intestinal drug-drug interactions: A PBPK simulation study using oxybutynin as a case example Thursday 15:10-16:40 |
IV-48 Kwan Cheol Pak Physiologically based pharmacokinetic modeling of Herceptin and human pharmacokinetic prediction Thursday 15:10-16:40 |
IV-61 Eduard Schmulenson A physiologically-based pharmacokinetic modeling approach to assess the impact of chronic kidney disease Thursday 15:10-16:40 |
IV-70 Christer Rimmler Evaluating New Dosing Strategies for the Use of Cefuroxime in Perioperative Antibiotic Prophylaxis using PBPK Thursday 15:10-16:40 |